Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
CONCLUSIONS: Measurement of faecal M2-PK levels lacks the specificity and sensitivity (and therefore diagnostic accuracy) to identify the individuals who should be progressed for clinical follow-up. Accordingly, M2-PK is not is not a robust biomarker for identifying pre-cancerous bowel lesions in a primary care setting.
PMID: 31465327 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
More News: Cancer | Cancer & Oncology | Colonoscopy | Colorectal Cancer | Gastrointestinal Polyps | General Medicine | New Zealand Health | Polyps | Primary Care